Company news
Shandong Buchang Pharmaceuticals Co., Ltd. Class A (SSE:603858) news
Shandong Buchang Pharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Mar 13, 2026: Announcement on the Transfer of Holding Subsidiary Equity
Press releases — page 2
Announcement on the Transfer of Holding Subsidiary Equity
March 12, 2026
Announcement on Participation in the Auction for the Qualification as a Restructuring Investor and Its Results
February 25, 2026
Announcement on Partial Drugs of the Subsidiary Being Selected for National Procurement Continuation After the Expiry of Agreement
February 11, 2026
Announcement on Pledge Release and Re-pledge of Partial Shares Held by Controlling Shareholder
February 10, 2026
Announcement on Resolutions of the 43rd Meeting of the 5th Board of Directors
February 9, 2026
Announcement on Progress in Proposed Waiver of Preemptive Rights for Equity of Holding Subsidiary and Related Party Transactions
February 4, 2026
Announcement on Wholly-owned Subsidiary Completing Industrial and Commercial Change Registration
February 2, 2026
Earnings Preannouncement for 2025
January 27, 2026
Announcement on the Plan of Share Repurchase through Call Auction and Obtaining of Commitment Letter on Special Loan for Repurchase from Financial Institution
January 16, 2026
Announcement on Holding Subsidiary Completing Industrial and Commercial Change Registration
January 7, 2026
Indicative Announcement on Changes in Fair Value of Trading Financial Assets
January 6, 2026
Announcement on the Recognition of Wholly-owned Subsidiary as a High-tech Enterprise Again
January 5, 2026
Announcement on Pledge of Controlling Shareholders' Shares
December 30, 2025
Announcement on the Execution of an Exclusive Supply Agreement between Holding Subsidiary Luzhou Buchang and MEDISPEC
December 29, 2025
Announcement on the Proposed Execution of a Technology Transfer Agreement by Wholly-owned Subsidiary Shandong Danhong with Shaanxi Functional Food Engineering Center Co., Ltd.
December 24, 2025